Quick Takeaways
- Avoro Capital Advisors LLC filed SCHEDULE 13G/A for ARROWHEAD PHARMACEUTICALS, INC. Common Stock, par value $0.001 per share (ARWR).
- Disclosed ownership: 8.3%.
- Date of event: 30 Jun 2025.
Avoro Capital Advisors LLC - 30 Jun 2025 SCHEDULE 13G/A Report for ARROWHEAD PHARMACEUTICALS, INC. Common Stock, par value $0.001 per share (ARWR)
- Filing Manager
- Avoro Capital Advisors LLC
- Reporting Manager
- Avoro Capital Advisors LLC
- Symbol
- ARWR
- Shares outstanding
- 138,764,349 shares
- Disclosed Ownership
- 11,517,441 shares
- Ownership
- 8.3%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 07:07:30 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Avoro Capital Advisors LLC disclosed 8.3% ownership in ARROWHEAD PHARMACEUTICALS, INC. Common Stock, par value $0.001 per share (ARWR) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 14 Aug 2025, 07:07.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 8.3% | 11,517,441 | 11,517,441 | 0 | /s/ Scott Epstein | Scott Epstein, Chief Financial Officer & Chief Compliance Officer | |
| Behzad Aghazadeh | 8.3% | 11,517,441 | 11,517,441 | 0 | /s/ Behzad Aghazadeh | Behzad Aghazadeh, Individually |